AI assistant
Tango Therapeutics, Inc. — Director's Dealing 2021
Aug 13, 2021
32459_dirs_2021-08-12_963df220-7ddf-44f8-ae8c-d45f09563d2c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Tango Therapeutics, Inc. (TNGX)
CIK: 0001819133
Period of Report: 2021-08-10
Reporting Person: Beckman Daniella (Chief Financial Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 63867 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.531 | 2029-10-18 | Common Stock (165443) | Direct | |
| Stock Option (Right to Buy) | $1.648 | 2030-01-30 | Common Stock (55204) | Direct | |
| Stock Option (Right to Buy) | $3.209 | 2030-10-01 | Common Stock (68114) | Direct | |
| Stock Option (Right to Buy) | $3.503 | 2031-01-28 | Common Stock (88157) | Direct |
Footnotes
F1: This option shall vest and become exercisable in equally monthly installments over a period of 48 months from September 10, 2019.
F2: This option shall vest and become exercisable in monthly installments over a period of 48 months from November 1, 2019.
F3: This option shall vest and become exercisable in monthly installments over a period of 48 months from July 1, 2020.
F4: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2021, with the remaining option shares vesting in 36 equal monthly installments thereafter.